Veracyte  
是一家在新兴的分子细胞学领域处于领先水平的分子诊断公司。Afirma基因表达检测可减少不必要的甲状腺癌手术风险,通过基因表达分类器检测Afirma基因的表达能降低超过一半以上不必要的甲状腺癌手术。

Veracyte, Inc., based in South San Francisco, Calif., is a privately held molecular diagnostics company pioneering the field of molecular cytology. The company is focused on discovering, developing and commercializing molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first product – the Afirma Thyroid FNA Analysis – was launched in 2011 and combines specialized cytopathology assessment with the Afirma Gene Expression Classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer. The company has a global co-promotion agreement with Genzyme, a Sanofi company, to make the Afirma Thyroid FNA Analysis more broadly available. Veracyte is privately held and funded by Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures. Veracyte and Afirma are registered trademarks of Veracyte, Inc. All rights reserved.